AzurRx announces “Positive Data” from its Phase 2 OPTION trial for Exocrine Pancreatic Insufficiency (EPI) in patients with Cystic Fibrosis
AzurRx BioPharma (NASDAQ: AZRX), a development stage company that is developing oral, nonsystemic, recombinant proteins for the treatment of gastrointestinal diseases, announced the results from a Phase II Clinical Trial of MS1819. The phase II trial named OPTION was an open-label, crossover trial being carried...
